These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 35384091)

  • 1. Editorial Comment to Safety and efficacy of apalutamide in Japanese patients with metastatic castration-sensitive prostate cancer receiving androgen deprivation therapy: Final report for the Japanese subpopulation analysis of the randomized, placebo-controlled, phase III TITAN study.
    Zang Z; Wang Z; Chiong E
    Int J Urol; 2022 Jun; 29(6):541. PubMed ID: 35384091
    [No Abstract]   [Full Text] [Related]  

  • 2. Safety and efficacy of apalutamide in Japanese patients with metastatic castration-sensitive prostate cancer receiving androgen deprivation therapy: Final report for the Japanese subpopulation analysis of the randomized, placebo-controlled, phase III TITAN study.
    Uemura H; Arai G; Uemura H; Suzuki H; Aoyama J; Hatayama T; Ito M; Lefresne F; McCarthy S; Mundle S; He J; Chi KN
    Int J Urol; 2022 Jun; 29(6):533-540. PubMed ID: 35293030
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Apalutamide for metastatic, castration-sensitive prostate cancer in the Japanese population: A subgroup analysis of the randomized, double-blind, placebo-controlled phase 3 TITAN study.
    Uemura H; Arai G; Uemura H; Suzuki H; Iijima K; Nishimura K; Fujii K; Hatayama T; Aoyama J; Deprince K; Lopez-Gitlitz A; McCarthy S; Larsen JS; Li J; Chi KN
    Int J Urol; 2021 Mar; 28(3):280-287. PubMed ID: 33295007
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Health-related quality of life after apalutamide treatment in patients with metastatic castration-sensitive prostate cancer (TITAN): a randomised, placebo-controlled, phase 3 study.
    Agarwal N; McQuarrie K; Bjartell A; Chowdhury S; Pereira de Santana Gomes AJ; Chung BH; Özgüroğlu M; Juárez Soto Á; Merseburger AS; Uemura H; Ye D; Given R; Cella D; Basch E; Miladinovic B; Dearden L; Deprince K; Naini V; Lopez-Gitlitz A; Chi KN;
    Lancet Oncol; 2019 Nov; 20(11):1518-1530. PubMed ID: 31578173
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Apalutamide and its use in the treatment of prostate cancer.
    Borno HT; Small EJ
    Future Oncol; 2019 Feb; 15(6):591-599. PubMed ID: 30426794
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Apalutamide for Metastatic, Castration-Sensitive Prostate Cancer.
    Chi KN; Agarwal N; Bjartell A; Chung BH; Pereira de Santana Gomes AJ; Given R; Juárez Soto Á; Merseburger AS; Özgüroğlu M; Uemura H; Ye D; Deprince K; Naini V; Li J; Cheng S; Yu MK; Zhang K; Larsen JS; McCarthy S; Chowdhury S;
    N Engl J Med; 2019 Jul; 381(1):13-24. PubMed ID: 31150574
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Apalutamide in Patients With Metastatic Castration-Sensitive Prostate Cancer: Final Survival Analysis of the Randomized, Double-Blind, Phase III TITAN Study.
    Chi KN; Chowdhury S; Bjartell A; Chung BH; Pereira de Santana Gomes AJ; Given R; Juárez A; Merseburger AS; Özgüroğlu M; Uemura H; Ye D; Brookman-May S; Mundle SD; McCarthy SA; Larsen JS; Sun W; Bevans KB; Zhang K; Bandyopadhyay N; Agarwal N
    J Clin Oncol; 2021 Jul; 39(20):2294-2303. PubMed ID: 33914595
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Editorial Comment to Apalutamide for metastatic, castration-sensitive prostate cancer in the Japanese population: A subgroup analysis of the randomized, double-blind, placebo-controlled phase 3 TITAN study.
    Sakamoto S
    Int J Urol; 2021 Mar; 28(3):288. PubMed ID: 33327040
    [No Abstract]   [Full Text] [Related]  

  • 9. Apalutamide for metastatic castration-sensitive prostate cancer: final analysis of the Asian subpopulation in the TITAN trial.
    Chung BH; Huang J; Uemura H; Choi YD; Ye ZQ; Suzuki H; Kang TW; He DL; Joung JY; Brookman-May SD; McCarthy S; Bhaumik A; Singh A; Mundle S; Chowdhury S; Agarwal N; Ye DW; Chi KN; Uemura H
    Asian J Androl; 2023 Nov; 25(6):653-661. PubMed ID: 37322621
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Apalutamide plus Androgen Deprivation Therapy for Metastatic Castration-Sensitive Prostate Cancer: Analysis of Pain and Fatigue in the Phase 3 TITAN Study.
    Agarwal N; McQuarrie K; Bjartell A; Chowdhury S; Pereira de Santana Gomes AJ; Chung BH; Özgüroğlu M; Juárez Soto Á; Merseburger AS; Uemura H; Ye D; Given R; Basch E; Miladinovic B; Lopez-Gitlitz A; Chi KN
    J Urol; 2021 Oct; 206(4):914-923. PubMed ID: 34039013
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Skin rash following Administration of Apalutamide in Japanese patients with Advanced Prostate Cancer: an integrated analysis of the phase 3 SPARTAN and TITAN studies and a phase 1 open-label study.
    Uemura H; Koroki Y; Iwaki Y; Imanaka K; Kambara T; Lopez-Gitlitz A; Smith A; Uemura H
    BMC Urol; 2020 Sep; 20(1):139. PubMed ID: 32878613
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Apalutamide efficacy, safety and wellbeing in older patients with advanced prostate cancer from Phase 3 randomised clinical studies TITAN and SPARTAN.
    Shen J; Chowdhury S; Agarwal N; Karsh LI; Oudard S; Gartrell BA; Feyerabend S; Saad F; Pieczonka CM; Chi KN; Brookman-May SD; Rooney B; Bhaumik A; McCarthy SA; Bevans KB; Mundle SD; Small EJ; Smith MR; Graff JN
    Br J Cancer; 2024 Jan; 130(1):73-81. PubMed ID: 37951974
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of apalutamide on health-related quality of life in patients with non-metastatic castration-resistant prostate cancer: an analysis of the SPARTAN randomised, placebo-controlled, phase 3 trial.
    Saad F; Cella D; Basch E; Hadaschik BA; Mainwaring PN; Oudard S; Graff JN; McQuarrie K; Li S; Hudgens S; Lawson J; Lopez-Gitlitz A; Yu MK; Smith MR; Small EJ
    Lancet Oncol; 2018 Oct; 19(10):1404-1416. PubMed ID: 30213449
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Apalutamide for patients with metastatic castrationsensitive prostate cancer in East Asia: a subgroup analysis of the TITAN trial.
    Chung BH; Huang J; Ye ZQ; He DL; Uemura H; Arai G; Kim CS; Zhang YY; Koroki Y; Jeong S; Mundle S; Triantos S; McCarthy S; Chi KN; Ye DW
    Asian J Androl; 2022; 24(2):161-166. PubMed ID: 34259202
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Apalutamide: A new agent in the management of prostate cancer.
    May MB; Glode AE
    J Oncol Pharm Pract; 2019 Dec; 25(8):1968-1978. PubMed ID: 31359832
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The addition of apalutamide to ADT in the treatment of metastatic castration-sensitive prostate cancer: safety and efficacy.
    Barata P; Swami U; Agarwal N
    Expert Rev Anticancer Ther; 2020 Mar; 20(3):147-150. PubMed ID: 32068456
    [No Abstract]   [Full Text] [Related]  

  • 17. Apalutamide: A Review in Metastatic Castration-Sensitive Prostate Cancer.
    Hoy SM
    Drugs; 2020 Oct; 80(15):1579-1585. PubMed ID: 32930958
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety exposure-response relationships of apalutamide in patients with metastatic castration-sensitive prostate cancer: results from the phase 3 TITAN study.
    T'jollyn H; Ackaert O; Chien C; Lopez-Gitlitz A; McCarthy S; Ruixo CP; Karsh L; Chi K; Chowdhury S; Ruixo JP; Agarwal N
    Cancer Chemother Pharmacol; 2022 May; 89(5):629-641. PubMed ID: 35366072
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An open-label, phase 1 study of androgen receptor antagonist, apalutamide in Japanese patients with metastatic castration-resistant prostate cancer.
    Tsuchiya T; Imanaka K; Iwaki Y; Oyama R; Hashine K; Yamaguchi A; Uemura H
    Int J Clin Oncol; 2019 Dec; 24(12):1596-1604. PubMed ID: 31446511
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of Prior Prostate Directed Local Therapy on Response to Apalutamide in Metastatic Hormone Sensitive Prostate Cancer: A Secondary Analysis of the TITAN Study.
    Roy S; Saad F; Malone S; Agarwal N; Mohamad O; Morgan SC; Malone J; Swami U; Jia AY; Gebrael G; Mendiratta P; Brown JR; Rao SK; Sun Y; Wallis CJD; Chi KN; Chowdhury S; Kishan AU; Spratt DE
    Eur Urol; 2024 Apr; 85(4):398-400. PubMed ID: 38485300
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.